XCath Executes World’s First Remote Robotic Stroke Surgery, Revolutionising Care Access

A UAE-backed healthtech startup has just pulled off something that, until recently, sounded more science fiction than hospital routine.

XCath, a medical robotics company part-owned by Crescent Enterprises, has completed what is being described as the world’s first in-human telerobotic stroke procedure. In simple terms, a surgeon treated a stroke patient from 200 kilometres away using a robotic system designed for delicate neurovascular work. And yes, it worked.

The procedure was a remote mechanical thrombectomy, the gold-standard treatment for an ischaemic stroke caused by a large vessel occlusion. The operation was carried out using XCath’s Iris Endovascular Robotic (EVR) System. Dr Vitor Mendes Pereira operated from a control room in Santiago, Panama, while the patient was at the Panama Clinic in Panama City. On-site support came from Dr Anastasio Ameijeiras Sibauste, who oversaw the intervention locally.

Stroke remains one of the leading causes of death and disability worldwide. More than 5 million people die each year, and around 80 million are living with post-stroke disability. Mechanical thrombectomy is proven to significantly reduce mortality and long-term damage. Yet access is shockingly limited. According to data cited from the American Heart Association, median global access to thrombectomy stands at just 2.79%. That figure alone is a bit of a wake-up call.

This is where telerobotics could change the game. XCath says its Iris system achieved submillimetre precision over a long-distance connection, with no noticeable latency during the procedure. The company had previously demonstrated the platform at Abu Dhabi Health in 2025 and followed up with remote aneurysm procedures in November the same year. This latest milestone pushes the concept further, into acute stroke care where every second counts. As doctors often put it, “time is brain” – patients can lose more than two million brain cells per minute without treatment.

Neeraj Agrawal, Executive Director of Crescent Enterprises and a board member at XCath, said the company had delivered a remote mechanical thrombectomy at the highest standard of care. He pointed to the UAE’s investments in AI, robotics and medical technology as part of the ecosystem enabling such breakthroughs. He also noted that regulatory and policy support will be key to making remote treatment more widely accessible.

Eduardo Fonseca, CEO of XCath, described the achievement as a major step towards a future where geography does not decide who receives lifesaving surgery. He credited the collaboration between neurovascular specialists, robotics engineers and backers including Crescent Enterprises. Among those involved were Dr Fred Moll and the clinical teams in both Panama City and Santiago.

Dr Pereira said the experience of performing the first-in-human procedure matched earlier simulations, with imperceptibly low latency and no workflow disruption. He highlighted again the problem of limited global access to thrombectomy and the importance of technological innovation in widening that access.

If you’ve spent any time around founders in the MENA healthtech space, you’ll know how often access is the sticking point. I remember speaking to a young startup team in Dubai last year who were trying to reduce ambulance response times with AI routing. Different niche, same frustration: the solution exists, the bottleneck is distribution. In that sense, XCath’s model of “bringing the surgeon to the patient”, rather than flying patients to major urban centres – feels spot on.

Of course, it’s still early days. The Iris system remains under development and has not yet been cleared for commercial distribution in any country. Scaling this kind of technology across borders, healthcare systems and regulators is no small task. On the flip side, the momentum is hard to ignore.

Notably, the milestone follows a $30 million Series C round co-led by Crescent Enterprises, bringing XCath’s total funding to $92 million since its founding in 2017. The capital is expected to support efforts to commercialise what the company describes as the world’s first commercially practical endovascular robot, alongside further clinical work in remote mechanical thrombectomy.

With campuses in Houston, home to the world’s largest medical centre, and Pangyo in South Korea, often dubbed the Silicon Valley of Korea, XCath has positioned itself at the crossroads of medicine and deep tech. For the UAE, there’s also a broader narrative at play: exporting advanced medical innovation to the world rather than just importing it.

I reckon we’ll look back at this moment as one of those quiet but pivotal shifts. Telerobotic surgery for stroke might sound ambitious, maybe even slightly futuristic. But if the early results hold and regulators come on board, it could redefine who gets treated in time, and who doesn’t. And in stroke care, that difference is everything.

🚀 Got exciting news to share?

If you're a startup founder, VC, or PR agency with big updates—funding rounds, product launches 📢, or company milestones 🎉 — AraGeek English wants to hear from you!

✉️ Send Us Your Story 👇

https://en.arageek.com/send-us-your-story-or-a-news-tip